Fisetin is a senotherapeutic that extends health and lifespanResearch in Context

Background: Senescence is a tumor suppressor mechanism activated in stressed cells to prevent replication of damaged DNA. Senescent cells have been demonstrated to play a causal role in driving aging and age-related diseases using genetic and pharmacologic approaches. We previously demonstrated that the combination of dasatinib and the flavonoid quercetin is a potent senolytic improving numerous age-related conditions including frailty, osteoporosis and cardiovascular disease. The goal of this study was to identify flavonoids with more potent senolytic activity. Methods: A panel of flavonoid polyphenols was screened for senolytic activity using senescent murine and human fibroblasts, driven by oxidative and genotoxic stress, respectively. The top senotherapeutic flavonoid was tested in mice modeling a progeroid syndrome carrying a p16INK4a-luciferase reporter and aged wild-type mice to determine the effects of fisetin on senescence markers, age-related histopathology, disease markers, health span and lifespan. Human adipose tissue explants were used to determine if results translated. Findings: Of the 10 flavonoids tested, fisetin was the most potent senolytic. Acute or intermittent treatment of progeroid and old mice with fisetin reduced senescence markers in multiple tissues, consistent with a hit-and-run senolytic mechanism. Fisetin reduced senescence in a subset of cells in murine and human adipose tissue, demonstrating cell-type specificity. Administration of fisetin to wild-type mice late in life restored tissue homeostasis, reduced age-related pathology, and extended median and maximum lifespan. Interpretation: The natural product fisetin has senotherapeutic activity in mice and in human tissues. Late life intervention was sufficient to yield a potent health benefit. These characteristics suggest the feasibility to translation to human clinical studies. Fund: NIH grants P01 AG043376 (PDR, LJN), U19 AG056278 (PDR, LJN, WLL), R24 AG047115 (WLL), R37 AG013925 (JLK), R21 AG047984 (JLK), P30 DK050456 (Adipocyte Subcore, JLK), a Glenn Foundation/American Federation for Aging Research (AFAR) BIG Award (JLK), Glenn/AFAR (LJN, CEB), the Ted Nash Long Life and Noaber Foundations (JLK), the Connor Group (JLK), Robert J. and Theresa W. Ryan (JLK), and a Minnesota Partnership Grant (AMAY-UMN#99)-P004610401–1 (JLK, EAA). Keywords: Senolytic, Aging, Progeria, Healthspan, Lifespan, Senescence

Abstract licence: CC BY-NC

• A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging · 2024

• Endothelial senescence in vascular diseases: current understanding and future opportunities in senotherapeutics · 2023

• Inflammation and aging: signaling pathways and intervention therapies · 2023

• Aging and aging-related diseases: from molecular mechanisms to interventions and treatments · 2022

• Immune Senescence, Immunosenescence and Aging · 2022

• Interconnections between Inflammageing and Immunosenescence during Ageing · 2022

• Senescence in osteoarthritis: from mechanism to potential treatment · 2022

• Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs · 2022

• Cellular senescence: a key therapeutic target in aging and diseases · 2022

• Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development · 2022

• Cellular Senescence in Brain Aging · 2021

• Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics · 2021

• Neuroinflammation in Alzheimer’s Disease · 2021

• Expression of concern

  The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice · 2021

• Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker · 2021

• Cellular senescence in musculoskeletal homeostasis, diseases, and regeneration · 2021

• Senolytics reduce coronavirus-related mortality in old mice · 2021

• Skin Aging, Cellular Senescence and Natural Polyphenols · 2021

• Therapy-Induced Senescence: An “Old” Friend Becomes the Enemy · 2020

• Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies · 2020

and 12 more

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.